Logo image
Se connecter
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Article de revue   Avec comité de lecture

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

C.E. Geyer, J.E. Garber, R.D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, …
Annals of oncology, Vol.33(12), pp.1250-1268
01/12/2022
PMID: 36228963

Résumé

adjuvant therapy BRCA1/2 breast cancer olaparib PARP inhibition

Détails

Logo image